103 results on '"Van den Hauwe M"'
Search Results
2. Correction to: Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study (Neurology and Therapy, (2023), 12, 2, (543-557), 10.1007/s40120-023-00444-1)
3. Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy
4. Gait stage classification for children with Duchenne muscular dystrophy based on longitudinal follow-up of progressive gait pathology
5. Instrumented strength assessment in typically developing children and children with a neural or neuromuscular disorder: Reliability, validity and responsiveness
6. Hammersmith Functional Motor Scale and Motor Function Measure-20 in non ambulant SMA patients
7. Six minute walk test in type III spinal muscular atrophy: A 12 month longitudinal study
8. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial
9. Development of a patient‐reported outcome measure for upper limb function in Duchenne muscular dystrophy: DMD Upper Limb PROM
10. Gait stage classification of children with Duchenne muscular dystrophy
11. Test-retest reliability and normative data of the six-minute walk test in healthy boys aged 5 to 12 years: C4–P2
12. Longitudinal alterations of gait features in growing boys with Duchenne muscular dystrophy
13. Treatment effect of idebenone on inspiratory function in patients with Duchenne muscular dystrophy
14. Development of a patient-reported outcome measure for upper limb function in Duchenne muscular dystrophy: DMD Upper Limb PROM
15. The association between muscle weakness and gait deviations in children with Duchenne muscular dystrophy
16. Are muscle volume and echo-intensity related to rate of force development in children with Duchenne muscular dystrophy?
17. Characterization of pulmonary function in 10–18 year old patients with Duchenne muscular dystrophy
18. Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials
19. Normative data and reference equation for the six-minute walk test in healthy Caucasian boys aged 13–18 years
20. Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy
21. Reference values for the three-minute walk test, North Star ambulatory assessment and timed tests in typically developing boys aged 2.5–5 years
22. Development of a patient-reported outcome measure for arm and hand function in Duchenne muscular dystrophy (UL-PROM DMD)
23. Assessment of early motor development in young boys with Duchenne muscular dystrophy
24. Hammersmith Functional Motor Scale and Motor Function Measure-20 in non ambulant SMA patients
25. Glucocorticoids influence therapeutic efficacy of idebenone (Catena (R)) on peak expiratory flow in patients with Duchenne muscular dystrophy (DMD)
26. P.2 - The association between muscle weakness and gait deviations in children with Duchenne muscular dystrophy
27. Six minute walk test in type III spinal muscular atrophy: a 12month longitudinal study
28. P.322 - Normative data and reference equation for the six-minute walk test in healthy Caucasian boys aged 13–18 years
29. O50 – 1933 Normative data of the 6-minute walk test in healthy boys aged 5–12 years and correlations with anthropometric variables and myometry
30. Six minute walk test in type III spinal muscular atrophy: A 12month longitudinal study
31. S.P.9 Development of an upper limb functional scale in dystrophinopathies
32. S.P.2 Disease progression as measured by the 6MWD in Duchenne Muscular Dystrophy; a single centre experience of 62 boys treated with daily corticosteroids
33. P4.8 Results from a two-year open label intervention study with idebenone (Catena®) in Duchenne muscular dystrophy
34. P4.27 Fourty eight-week follow-up data from a Phase I/IIa extension study of systemic PRO051/GSK2402968 in Duchenne muscular dystrophy: Comparison with contemporaneous controls for 6-min walking distance test
35. G.P.144 - Reference values for the three-minute walk test, North Star ambulatory assessment and timed tests in typically developing boys aged 2.5–5 years
36. G.P.145 - Assessment of early motor development in young boys with Duchenne muscular dystrophy
37. G.P.139 - Development of a patient-reported outcome measure for arm and hand function in Duchenne muscular dystrophy (UL-PROM DMD)
38. T.P.3.01 Glucocorticoids influence therapeutic efficacy of idebenone (Catena®) on peak expiratory flow in patients with Duchenne muscular dystrophy (DMD)
39. M.P.3.01 Gait steadiness and upper-body kinematics in DMD children
40. M.P.3.02 Detailed analysis of daily-life physical activity patterns in DMD children
41. A CINRG PILOT TRIAL OF OXATOMIDE IN STEROID-NAÏVE DUCHENNE MUSCULAR DYSTROPHY
42. Detailed analysis of daily-life physical activity patterns in DMD children
43. Gait steadiness and upper-body kinematics in DMD children
44. Gait Assessment in Duchenne Muscular Dystrophy Children during Long-Distance Walking
45. Characterization of pulmonary function in 10–18 year old patients with Duchenne muscular dystrophy
46. T.P.3.01 Glucocorticoids influence therapeutic efficacy of idebenone (Catena®) on peak expiratory flow in patients with Duchenne muscular dystrophy (DMD)
47. P.468 - Are muscle volume and echo-intensity related to rate of force development in children with Duchenne muscular dystrophy?
48. G.P.10 07 CINRG pilot trial of oxatomide in steroid-naive Duchenne muscular dystrophy
49. Gait classification for growing children with Duchenne muscular dystrophy.
50. Respiratory morbidity in patients with spinal muscular atrophy-a changing world in the light of disease-modifying therapies.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.